Medical Supplies Stock Performance Review -- Tandem Diabetes Care, Merit Medical Systems, Hill Rom, and Microbot Medical

02:52 EDT 2 Aug 2017 | PR Newswire

NEW YORK, August 2, 2017 /PRNewswire/ --

If you want a Stock Review on TNDM, MMSI, HRC, or MBOT then come over to and sign up for your free customized report today. Medical Instruments and Supplies companies manufacture a broad range of non-electromedical equipment, with many of the industry's largest firms producing dozens of different industry-relevant instruments and supplies. This diversity of product lines insulates companies (and, in turn, the industry, as a whole) from extreme volatility, as fluctuations in demand for any one specific product has only a limited impact on overall revenue. In today's pre-market research, takes a closer look at Tandem Diabetes Care Inc. (NASDAQ: TNDM), Merit Medical Systems Inc. (NASDAQ: MMSI), Hill-Rom Holdings Inc. (NYSE: HRC), and Microbot Medical Inc. (NASDAQ: MBOT). These free stocks reports are currently available on Simply sign up for your complimentary member access at:

Tandem Diabetes Care 

San Diego, California headquartered Tandem Diabetes Care Inc.'s stock finished Tuesday's session 19.09% lower at $0.39. A total volume of 1.24 million shares was traded, which was above their three months average volume of 383,790 shares. The Company's shares are trading below their 50-day moving average by 48.50%. Moreover, shares of the Company, which designs, develops, and commercializes various products for people with insulin-dependent diabetes in the US, have a Relative Strength Index (RSI) of 22.58.

On July 27th, 2017, Tandem Diabetes Care reported its financial results for the quarter ended June 30th, 2017. GAAP sales for Q2 2017 were $21.3 million; gross margin was 38%; operating expenses totaled $27.0 million; GAAP operating loss was $19.0 million; and GAAP operating margin was -89%. As of June 30th, 2017, the Company had $37.8 million in cash, cash equivalents, short-term investments, and restricted cash. Your complete research report on TNDM can be retrieved for free at:

Merit Medical Systems 

Shares in South Jordan, Utah headquartered Merit Medical Systems Inc. rose 1.59%, ending yesterday's session at $41.65. A total volume of 571,641 shares was traded, which was above their three months average volume of 404,740 shares. The stock has gained 9.17% in the past month, 23.59% in the previous three months, and 57.17% on an YTD basis. The Company's shares are trading 12.87% above their 50-day moving average and 40.35% above their 200-day moving average. Moreover, shares of Merit Medical Systems, which designs, develops, manufactures, and markets medical products for interventional and diagnostic procedures worldwide, have an RSI of 66.76.  

On July 20th, 2017, research firm Bank of America/ Merrill initiated a 'Buy' rating on the Company's stock, with a target price of $44 per share.

On July 31st, 2017, Merit Medical Systems announced that Chairman and Chief Executive Officer Fred P. Lampropoulos will host one-on-one meetings at the 2nd Annual Needham MedTech 1x1 Conference on August 08th, 2017, at the Needham offices in Boston. Lampropoulos will also present at the Canaccord Genuity's 37th Annual Growth Conference on August 09th, 2017, at 3:30 p.m. ET at the InterContinental Boston. A free report on MMSI is just a click away at:

Hill Rom 

On Tuesday, Chicago, Illinois headquartered Hill-Rom Holdings Inc.'s stock climbed 0.66%, to close the day at $75.01. A total volume of 745,975 shares was traded, which was above their three months average volume of 482,740 shares. The Company's shares have advanced 33.61% on an YTD basis. The stock is trading 11.82% above its 200-day moving average. Additionally, shares of Hill-Rom, which operates as a medical technology company worldwide, have an RSI of 32.00.  

On July 19th, 2017, Hill-Rom announced that its board of directors declared a Q4 FY17 dividend of $0.18 per share, payable on September 29th, 2017, to shareholders of record as of the close of business on September 15th, 2017. The indicated annual dividend rate is $0.72 per share.

On July 28th, 2017, research firm Needham reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $95 a share to $93 a share. Sign up for your complimentary research report on HRC at:

Microbot Medical 

Shares in Yokneam, Israel-based Microbot Medical Inc. ended the day 4.11% lower at $1.40. A total volume of 2.21 million shares was traded, which was above their three months average volume of 996,200 shares. The stock is trading below its 50-day moving average by 28.45%. Furthermore, shares of Microbot Medical, which engages in the research, design, development, and commercialization of micro-robotics medical technologies, have an RSI of 39.94. Register for free on and download the latest research report on MBOT at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


More From BioPortfolio on "Medical Supplies Stock Performance Review -- Tandem Diabetes Care, Merit Medical Systems, Hill Rom, and Microbot Medical"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...